Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 16, 2026, 5:14 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 361–384 of 813 matching trials from the live ClinicalTrials.gov search.
Conditions
Attention Deficit Hyperactivity Disorder (ADHD)
Interventions
Behavioral assessment and NAT EEG tests
Other
Lead sponsor
Think Now Incorporated
Industry
Eligibility
18 Years to 40 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Los Angeles, California
Completed Phase 4 Interventional Results available

Attention Deficit Disorder Medication Response Study

NCT01727414
Conditions
ADHD - Inattentive Type, ADHD - Combined Type
Interventions
OROS-Methylphenidate and placebo for inattentive type pts, OROS-Methylphenidate and placebo for combined type pts
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
7 Years to 11 Years
Enrollment
171 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
1
States / cities
Cincinnati, Ohio
Conditions
Leukodystrophy, White Matter Disease, 4H Syndrome, Adrenoleukodystrophy, AMN, ALD, ALD (Adrenoleukodystrophy), X-linked Adrenoleukodystrophy, X-ALD, Adrenomyeloneuropathy, Aicardi Goutieres Syndrome, AGS, Alexander Disease, Alexanders Leukodystrophy, AxD, ADLD, Canavan Disease, CTX, Cerebrotendinous Xanthomatoses, Krabbe Disease, GALC Deficiency, Globoid Leukodystrophy, TUBB4A-Related Leukodystrophy, H-ABC - Hypomyelination, Atrophy of Basal Ganglia and Cerebellum, HBSL, HBSL - Hypomyelination, Brain Stem, Spinal Cord, Leg Spasticity, LBSL, Leukoencephalopathy With Brain Stem and Spinal Cord Involvement and High Lactate Syndrome (Disorder), Leukoencephalopathy With Brainstem and Spinal Cord Involvement and Lactate Elevation, ALSP, CSF1R Gene Mutation, HCC - Hypomyelination and Congenital Cataract, MLC1, Megalencephalic Leukoencephalopathy With Subcortical Cysts 1, MLD, Metachromatic Leukodystrophy, PMD, Pelizaeus-Merzbacher Disease, PLP1 Null Syndrome, PLP1 Gene Duplication | Blood or Tissue | Mutations, Pelizaeus-Merzbacher-Like Disease, 1, Peroxisomal Biogenesis Disorder, Zellweger Syndrome, Refsum Disease, Salla Disease, Sialic Storage Disease, Sjögren, Sjogren-Larsson Syndrome, Van Der Knapp Disease, Vanishing White Matter Disease, Charcot-Marie-Tooth, CMT, Mct8 (Slc16A2)-Specific Thyroid Hormone Cell Transporter Deficiency, Allan-Herndon-Dudley Syndrome, Cadasil, Cockayne Syndrome, Multiple Sulfatase Deficiency, Gangliosidoses, GM2 Gangliosidosis, BPAN, Labrune Syndrome, LCC, Mucopolysaccharidoses, TBCK-Related Intellectual Disability Syndrome
Interventions
Not listed
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
Up to 18 Years
Enrollment
236 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Long-Duration Stimulant Treatment Study of ADHD in Young Children

NCT00257725
Conditions
Attention Deficit Disorder With Hyperactivity
Interventions
B-MPH
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
4 Years to 5 Years
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2008
U.S. locations
1
States / cities
New York, New York
Conditions
Attention Deficit Disorder With Hyperactivity
Interventions
CTN SR, Matching placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
4
States / cities
Newport Beach, California • Bradenton, Florida • Maitland, Florida + 1 more
Completed Not applicable Interventional Accepts healthy volunteers Results available

Atomoxetine for Attention Deficit Hyperactivity Disorder in Adolescents With Substance Use Disorder

NCT00399763
Conditions
Attention Deficit Hyperactivity Disorder, Substance Abuse
Interventions
Atomoxetine, Placebo
Drug
Lead sponsor
Denver Health and Hospital Authority
Other
Eligibility
12 Years to 19 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2008
U.S. locations
1
States / cities
Denver, Colorado
Conditions
ADHD
Interventions
methylphenidate transdermal system, Placebo
Drug
Lead sponsor
Noven Therapeutics
Industry
Eligibility
13 Years to 17 Years
Enrollment
217 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
32
States / cities
Scottsdale, Arizona • Lafayette, California • Wildomar, California + 29 more
Completed No phase listed Observational Accepts healthy volunteers

Study of Cognition and Control in Youths

NCT03393390
Conditions
Attention Deficit Hyperactivity Disorder, Oppositional Defiant Disorder, Conduct Disorder
Interventions
Clinical Assessment Visit, fMRI scan
Diagnostic Test · Other
Lead sponsor
University of Michigan
Other
Eligibility
6 Years to 18 Years
Enrollment
256 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
1
States / cities
Ann Arbor, Michigan
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Daily Report Card, Language Intervention
Behavioral · Other
Lead sponsor
Florida International University
Other
Eligibility
Not listed
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Miami, Florida
Conditions
Asperger's Disorder, Asperger Disorder, Autism Disorder, Autism, ADHD - Attention Deficit Disorder With Hyperactivity, ADHD, ASD, Alcohol Abuse/Dependence, Alcohol Addiction, Alcohol and Other Drug Use Disorders, Alcohol and Other Substance Use Prevention, Gambling Addiction, Gambling Disorder, Sex Abuse, Sex Behavior, Sex Crimes, Sex Disorder, Sex Disorders, Gender Dysphoria, Adult, Eating Behavior Disorders, Narcotic-Related Disorders, Narcotic Addiction, Narcissism, Psychiatric Disorder, Psychedelic Effects in Healthy Volunteers, Psychedelic Experiences, Psychedelic Drug Dependence, Marijuana Use Disorder, Marijuana Abuse and Dependence, Smoking (Tobacco) Addiction, Smoking Among Youth, Smoking Abstinence, Abstinence, Sex, Opiate Substitution Treatment, Opioid Abuse (Disorder), Opioid Abuse and Addiction, Cocaine Abuse, MDMA ('Ecstasy'), Addiction Disorders, Homeless and Low Incomes People, Refugees, Homelessness, Reliability and Validity, Anger Problems, Child Abuse, Sexual
Interventions
AI City Hall Project (AIhealth4u - Public Health Central), AI City Hall Project (QAIAx Microcity A - AI Public Health Central)
Behavioral
Lead sponsor
Veterans Recovery Network Inc.
Other
Eligibility
17 Years to 99 Years
Enrollment
1,000,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2045
U.S. locations
1
States / cities
Richmond, Virginia
Conditions
Cocaine-Related Disorders, Substance-Related Disorders
Interventions
Methylphenidate
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
21 Years to 50 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 1999
U.S. locations
1
States / cities
Cincinnati, Ohio
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Mindfulness-Based ADHD Treatment for Children, Goal-Standard Medication (Treatment as Usual)
Behavioral · Biological
Lead sponsor
Yale University
Other
Eligibility
7 Years to 13 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
New Haven, Connecticut
Conditions
Attention Deficit Disorder With Hyperactivity
Interventions
Aptensio XR
Drug
Lead sponsor
Rhodes Pharmaceuticals, L.P.
Industry
Eligibility
4 Years to 6 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
2
States / cities
Las Vegas, Nevada • Durham, North Carolina
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
ADHD Collaborative
Other
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
Not listed
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Cincinnati, Ohio
Completed No phase listed Observational Accepts healthy volunteers

Attention Deficit Disorder and Exposure to Lead

NCT00014898
Conditions
Attention Deficit Disorder
Interventions
Not listed
Lead sponsor
National Institute of Environmental Health Sciences (NIEHS)
NIH
Eligibility
10 Years to 18 Years
Enrollment
500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1999 – 2002
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Conditions
ADHD
Interventions
CLS-A-FUERTE
Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
5 Years and older
Enrollment
872 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
San Francisco, California
Conditions
ADHD
Interventions
ADHD Therapy, Control Therapy
Device
Lead sponsor
Lumos Labs, Inc.
Industry
Eligibility
22 Years to 55 Years
Enrollment
560 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
13
States / cities
Scottsdale, Arizona • Garden Grove, California • Sacramento, California + 10 more
Conditions
Childhood Disruptive Behavior Disorders, Oppositional Defiant Disorder, Conduct Disorder, Attention Deficit Hyperactivity Disorder, Parent-Child Interactions
Interventions
Triple P--Positive Parenting Program
Behavioral
Lead sponsor
University of South Carolina
Other
Eligibility
3 Years to 7 Years
Enrollment
334 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
2
States / cities
Eugene, Oregon • Columbia, South Carolina
Conditions
Attention Deficit Disorder With Hyperactivity
Interventions
Not listed
Lead sponsor
University of California, Los Angeles
Other
Eligibility
5 Years to 12 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
3
States / cities
Los Angeles, California • Northridge, California
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Digital Treatment
Other
Lead sponsor
Akili Interactive Labs, Inc.
Industry
Eligibility
18 Years and older
Enrollment
223 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
14
States / cities
Scottsdale, Arizona • Garden Grove, California • Lauderhill, Florida + 11 more
Conditions
ADHD, Attention-Deficit/Hyperactivity Disorder, Predominantly Inattentive Type
Interventions
MG01CI (1400 mg), placebo
Drug
Lead sponsor
Alcobra Ltd.
Industry
Eligibility
18 Years to 55 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
18
States / cities
Gainesville, Florida • South Miami, Florida • Libertyville, Illinois + 15 more
Conditions
ADHD
Interventions
Attention Deficit Hyperactivity Disorder Treatment Decision Aid
Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
512 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Boston, Massachusetts
Completed No phase listed Observational Accepts healthy volunteers

Neurophysiological Attention Test (NAT) for Objective Assessment of Adult ADHD

NCT02756286
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
NAT electroencephalography (EEG) test
Other
Lead sponsor
Think Now Incorporated
Industry
Eligibility
18 Years to 40 Years
Enrollment
258 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
3
States / cities
Berkeley, California • Los Angeles, California • Portland, Oregon
Withdrawn No phase listed Observational Accepts healthy volunteers

Clinical Applications of High-Frequency Oscillations

NCT00600717
Conditions
Epilepsy, Migraine, Headache, Pain, Autism, Cerebral Palsy, Brain Development, Traumatic Brain Injury, ADHD - Attention Deficit Disorder With Hyperactivity, Mental Health
Interventions
Not listed
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
1 Day to 69 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2027
U.S. locations
1
States / cities
Cincinnati, Ohio